Use of aspirin associates with longer primary patency of hemodialysis grafts

Bradley S. Dixon, Gerald J. Beck, Laura M. Dember, Miguel A. Vazquez, Arthur Greenberg, James A. Delmez, Michael Allon, Jonathan Himmelfarb, Bo Hu, Tom Greene, Milena K. Radeva, Ingemar J. Davidson, T. Alp Ikizler, Gregory L. Braden, Jeffrey H. Lawson, James R. Cotton, John W. Kusek, Harold I. Feldman

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Extended-release dipyridamole plus low-dose aspirin (ERDP/ASA) prolongs primary unassisted graft patency of newly created hemodialysis arteriovenous grafts, but the individual contributions of each component are unknown. Here, we analyzed whether use of aspirin at baseline associated with primary unassisted graft patency among participants in a randomized trial that compared ERDP/ASA and placebo in newly created grafts. We used Cox proportional hazards regression, adjusting for prespecified baseline comorbidities and covariates. Of all participants, 43% reported use of aspirin at baseline; of these, 82% remained on nonstudy aspirin (i.e., excluding ERDP/ASA) at 1 year. After 1 year of follow-up, the incidence of primary unassisted patency among participants using aspirin at baseline was 30% (95% CI: 24 to 35%) and among those not using aspirin was 23% (95% CI: 18 to 27%). Use of aspirin at baseline associated with a dose-dependent prolongation of primary unassisted graft patency that approached statistical significance (adjusted HR, 0.83; 95% CI: 0.68 to 1.01; P = 0.06). Use of aspirin at baseline did not associate with prolongation of cumulative graft patency or participant survival. In conclusion, use of aspirin associates with a trend toward longer primary unassisted patency of newly placed hemodialysis grafts similar to that observed for ERDP/ASA.

Original languageEnglish (US)
Pages (from-to)773-781
Number of pages9
JournalJournal of the American Society of Nephrology
Volume22
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

Aspirin
Renal Dialysis
Transplants
Dipyridamole
Comorbidity
Placebos
Incidence

ASJC Scopus subject areas

  • Nephrology

Cite this

Dixon, B. S., Beck, G. J., Dember, L. M., Vazquez, M. A., Greenberg, A., Delmez, J. A., ... Feldman, H. I. (2011). Use of aspirin associates with longer primary patency of hemodialysis grafts. Journal of the American Society of Nephrology, 22(4), 773-781. https://doi.org/10.1681/ASN.2010060582

Use of aspirin associates with longer primary patency of hemodialysis grafts. / Dixon, Bradley S.; Beck, Gerald J.; Dember, Laura M.; Vazquez, Miguel A.; Greenberg, Arthur; Delmez, James A.; Allon, Michael; Himmelfarb, Jonathan; Hu, Bo; Greene, Tom; Radeva, Milena K.; Davidson, Ingemar J.; Ikizler, T. Alp; Braden, Gregory L.; Lawson, Jeffrey H.; Cotton, James R.; Kusek, John W.; Feldman, Harold I.

In: Journal of the American Society of Nephrology, Vol. 22, No. 4, 04.2011, p. 773-781.

Research output: Contribution to journalArticle

Dixon, BS, Beck, GJ, Dember, LM, Vazquez, MA, Greenberg, A, Delmez, JA, Allon, M, Himmelfarb, J, Hu, B, Greene, T, Radeva, MK, Davidson, IJ, Ikizler, TA, Braden, GL, Lawson, JH, Cotton, JR, Kusek, JW & Feldman, HI 2011, 'Use of aspirin associates with longer primary patency of hemodialysis grafts', Journal of the American Society of Nephrology, vol. 22, no. 4, pp. 773-781. https://doi.org/10.1681/ASN.2010060582
Dixon, Bradley S. ; Beck, Gerald J. ; Dember, Laura M. ; Vazquez, Miguel A. ; Greenberg, Arthur ; Delmez, James A. ; Allon, Michael ; Himmelfarb, Jonathan ; Hu, Bo ; Greene, Tom ; Radeva, Milena K. ; Davidson, Ingemar J. ; Ikizler, T. Alp ; Braden, Gregory L. ; Lawson, Jeffrey H. ; Cotton, James R. ; Kusek, John W. ; Feldman, Harold I. / Use of aspirin associates with longer primary patency of hemodialysis grafts. In: Journal of the American Society of Nephrology. 2011 ; Vol. 22, No. 4. pp. 773-781.
@article{68fdd6a951bb4bd09955bd13c56c28fa,
title = "Use of aspirin associates with longer primary patency of hemodialysis grafts",
abstract = "Extended-release dipyridamole plus low-dose aspirin (ERDP/ASA) prolongs primary unassisted graft patency of newly created hemodialysis arteriovenous grafts, but the individual contributions of each component are unknown. Here, we analyzed whether use of aspirin at baseline associated with primary unassisted graft patency among participants in a randomized trial that compared ERDP/ASA and placebo in newly created grafts. We used Cox proportional hazards regression, adjusting for prespecified baseline comorbidities and covariates. Of all participants, 43{\%} reported use of aspirin at baseline; of these, 82{\%} remained on nonstudy aspirin (i.e., excluding ERDP/ASA) at 1 year. After 1 year of follow-up, the incidence of primary unassisted patency among participants using aspirin at baseline was 30{\%} (95{\%} CI: 24 to 35{\%}) and among those not using aspirin was 23{\%} (95{\%} CI: 18 to 27{\%}). Use of aspirin at baseline associated with a dose-dependent prolongation of primary unassisted graft patency that approached statistical significance (adjusted HR, 0.83; 95{\%} CI: 0.68 to 1.01; P = 0.06). Use of aspirin at baseline did not associate with prolongation of cumulative graft patency or participant survival. In conclusion, use of aspirin associates with a trend toward longer primary unassisted patency of newly placed hemodialysis grafts similar to that observed for ERDP/ASA.",
author = "Dixon, {Bradley S.} and Beck, {Gerald J.} and Dember, {Laura M.} and Vazquez, {Miguel A.} and Arthur Greenberg and Delmez, {James A.} and Michael Allon and Jonathan Himmelfarb and Bo Hu and Tom Greene and Radeva, {Milena K.} and Davidson, {Ingemar J.} and Ikizler, {T. Alp} and Braden, {Gregory L.} and Lawson, {Jeffrey H.} and Cotton, {James R.} and Kusek, {John W.} and Feldman, {Harold I.}",
year = "2011",
month = "4",
doi = "10.1681/ASN.2010060582",
language = "English (US)",
volume = "22",
pages = "773--781",
journal = "Journal of the American Society of Nephrology",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "4",

}

TY - JOUR

T1 - Use of aspirin associates with longer primary patency of hemodialysis grafts

AU - Dixon, Bradley S.

AU - Beck, Gerald J.

AU - Dember, Laura M.

AU - Vazquez, Miguel A.

AU - Greenberg, Arthur

AU - Delmez, James A.

AU - Allon, Michael

AU - Himmelfarb, Jonathan

AU - Hu, Bo

AU - Greene, Tom

AU - Radeva, Milena K.

AU - Davidson, Ingemar J.

AU - Ikizler, T. Alp

AU - Braden, Gregory L.

AU - Lawson, Jeffrey H.

AU - Cotton, James R.

AU - Kusek, John W.

AU - Feldman, Harold I.

PY - 2011/4

Y1 - 2011/4

N2 - Extended-release dipyridamole plus low-dose aspirin (ERDP/ASA) prolongs primary unassisted graft patency of newly created hemodialysis arteriovenous grafts, but the individual contributions of each component are unknown. Here, we analyzed whether use of aspirin at baseline associated with primary unassisted graft patency among participants in a randomized trial that compared ERDP/ASA and placebo in newly created grafts. We used Cox proportional hazards regression, adjusting for prespecified baseline comorbidities and covariates. Of all participants, 43% reported use of aspirin at baseline; of these, 82% remained on nonstudy aspirin (i.e., excluding ERDP/ASA) at 1 year. After 1 year of follow-up, the incidence of primary unassisted patency among participants using aspirin at baseline was 30% (95% CI: 24 to 35%) and among those not using aspirin was 23% (95% CI: 18 to 27%). Use of aspirin at baseline associated with a dose-dependent prolongation of primary unassisted graft patency that approached statistical significance (adjusted HR, 0.83; 95% CI: 0.68 to 1.01; P = 0.06). Use of aspirin at baseline did not associate with prolongation of cumulative graft patency or participant survival. In conclusion, use of aspirin associates with a trend toward longer primary unassisted patency of newly placed hemodialysis grafts similar to that observed for ERDP/ASA.

AB - Extended-release dipyridamole plus low-dose aspirin (ERDP/ASA) prolongs primary unassisted graft patency of newly created hemodialysis arteriovenous grafts, but the individual contributions of each component are unknown. Here, we analyzed whether use of aspirin at baseline associated with primary unassisted graft patency among participants in a randomized trial that compared ERDP/ASA and placebo in newly created grafts. We used Cox proportional hazards regression, adjusting for prespecified baseline comorbidities and covariates. Of all participants, 43% reported use of aspirin at baseline; of these, 82% remained on nonstudy aspirin (i.e., excluding ERDP/ASA) at 1 year. After 1 year of follow-up, the incidence of primary unassisted patency among participants using aspirin at baseline was 30% (95% CI: 24 to 35%) and among those not using aspirin was 23% (95% CI: 18 to 27%). Use of aspirin at baseline associated with a dose-dependent prolongation of primary unassisted graft patency that approached statistical significance (adjusted HR, 0.83; 95% CI: 0.68 to 1.01; P = 0.06). Use of aspirin at baseline did not associate with prolongation of cumulative graft patency or participant survival. In conclusion, use of aspirin associates with a trend toward longer primary unassisted patency of newly placed hemodialysis grafts similar to that observed for ERDP/ASA.

UR - http://www.scopus.com/inward/record.url?scp=79953321405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953321405&partnerID=8YFLogxK

U2 - 10.1681/ASN.2010060582

DO - 10.1681/ASN.2010060582

M3 - Article

VL - 22

SP - 773

EP - 781

JO - Journal of the American Society of Nephrology

JF - Journal of the American Society of Nephrology

SN - 1046-6673

IS - 4

ER -